Table 1 Summary for FPO trials internationally excluding indications for HGGs. Trial details retrieved from ClinicalTrials.gov, accessed April 202575,88,89.
Study title | Type of cancer | Type of patients | Estimated enrollment | NCT number | Study location | Study type | Status | Start date | Expected date of completion | References (where available) |
|---|---|---|---|---|---|---|---|---|---|---|
Targeted Therapy Selection Based on Tumor Tissue Kinase Activity Profiles for Patients with Advanced Solid Malignancies, an Exploratory Study (TSAP) | Advanced (unresectable and/or metastatic) solid malignancy for whom no standard treatment is available | Adults | 45 | NCT01190241 | TN, USA | Interventional | Terminated | 01 August 2010 | 01 December 2027 | |
Personalized Patient Derived Xenograft (pPDX) Modelling to Test Drug Response in Matching Host | Colorectal, breast, and ovarian neoplasms | Adults | 120 | NCT02732860 | Ontario, Canada | Observational | Recruiting | 01 December 2015 | 04 January 2026 | Nil |
Beat AML Core Study | Acute myeloid leukemia (AML) | Adults (>18 years) | 22 | NCT02927106 | FL, USA | Observational | Completed | 15 February 2017 | 29 July 2020 | Nil |
Study of the Therapeutic Response and Survival of Patients with Metastatic Colorectal Cancer (stage IV) and Treated According to the Guidelines of a Chemosensitivity Test, Oncogramme (ONCOGRAM) (ONCOGRAM) | Metastatic colorectal cancer | Adults (>18 years) | 256 | NCT03133273 | Limoges, France | Interventional | Completed | 24 July 2017 | 03 April 2024 | |
PRecISion Medicine for Children With Cancer (PRISM) | High-risk childhood cancers with expected survival < 30% | Up to 21 years old | 550 | NCT03336931 | Sydney, Australia | Observational | Active, not recruiting | 05 September 2017 | 01 December 2023 | |
Personalized Precision Diagnosis and Treatment of Pancreatic Cancer (PPDTPC) | Pancreatic cancer | Adults (20 years to 75 years) | 100 | NCT04373928 | Shanghai, China | Interventional | Recruiting | 10 November 2017 | 31 December 2024 | Nil |
High Throughput Drug Sensitivity and Genomics Data in Developing Individualized Treatment in Patients with Relapsed or Refractory Multiple Myeloma or Plasma Cell Leukemia | Plasma cell leukemia/recurrent and relapsed multiple myeloma | Adults (>18 years) | 40 | NCT03389347 | Seattle, WA, USA | Interventional | Active, not recruiting | 14 February 2018 | 19 December 2026 | |
Patient-Derived Xenografts in Personalizing Treatment for Patients with Relapsed/ Refractory Mantle Cell Lymphoma | Relapsed/ Refractory Mantle Cell Lymphoma | Adults (>18 years) | 1 | NCT03219047 | TX, USA | Interventional | Completed | 20 December 2018 | 03 July 2023 | Nil |
Ex Vivo Drug Sensitivity Testing and Mutation Profiling | Recurrent or refractory cancer | Up to 21 years old | 25 | NCT03860376 | FL, USA | Observational | Completed | 21 February 2019 | 31 December 2022 | |
The PIONEER Initiative: Precision Insights on N-of-1 Ex Vivo Effectiveness Research Based on Individual Tumor Ownership (Precision Oncology) (PIONEER) | Any cancer | 1 Month to 99 years (child, adult, older adult) | 1000 | NCT03896958 | GA, USA | Observational | Unknown status | 21 March 2019 | 12 March 2024 | Nil |
Novel 3D Hematological Malignancy Organoid to Study Disease Biology and Chemosensitivity (Organoid) | Hematologic malignancy | Adults (>18 years) | 70 | NCT03890614 | NC, USA | Observational | Recruiting | 16 May 2019 | 01 February 2026 | Nil |
Q-GAIN (Using Qpop to Predict Treatment for Gastrointestinal caNcer) | Gastrointestinal cancers | Adults | 100 | NCT04611035 | Singapore | Observational | Unknown status | 20 January 2020 | 01 January 2023 | Nil |
Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial | metastatic solid tumor or hematological malignancy | Adults (>18 years) | 2 | NCT03878524 | OR, USA | Interventional | Terminated | 01 April 2020 | 10 December 2020 | Nil |
Comprehensive Genomic Profiling and Next Generation Functional Drug Screening for Patients with Aggressive Hematological Malignancies | Advanced and refractory lymphoma/refractory leukemia/refractory AML/refractory T cell lymphoma | Adults | 150 | NCT04470947 | Vienna, Austria | Observational | Recruiting | 10 June 2020 | 31 March 2026 | |
Feasibility Study of Multi-Platform Profiling of Resected Biliary Tract Cancer | Biliary Tract Cancer | Adults (>18 years) | 14 | NCT04561453 | Washington, USA | Observational | Active, not recruiting | 08 July 2020 | 01 July 2026 | |
Using QPOP to Predict Treatment for Sarcomas and Melanomas | Sarcoma, melanoma | Adults | 100 | NCT04986748 | Singapore | Observational | Recruiting | 08 September 2020 | 31 December 2028 | |
Hyper-Personalized Medicine Using Patient Derived Xenografts (PDXovo) for Metastatic Solid Tumors (PDXovo) | Metastatic solid tumors | Adults (>18 years) | 50 | NCT04602702 | Ontario, Canada | Observational | Unknown status | 01 December 2020 | 31 December 2022 | Nil |
Guided Treatment Based on Mini-PDX in Metastatic Triple Negative Breast Cancer | Triple Negative Breast Cancer | Adults (>18 years) | 100 | NCT04745975 | Shanghai, China | Interventional | Unknown status | 01 February 2021 | 01 January 2023 | Nil |
FPO for Metastatic Breast Cancer | HER2-negative breast cancer | Adults | 15 | NCT04450706 | UT, USA | Interventional | Completed | 16 February 2021 | 05 September 2024 | Nil |
3D Bioprinted Models for Predicting Chemotherapy Response in Colorectal Cancer with/without Liver Metastases | Colorectal cancer | Adults (>18 years) | 120 | NCT04755907 | Beijing, China | Observational | Unknown status | 01 March 2021 | 31 December 2023 | |
High Throughput Screening Device Based on 3D Nano-matrices and 3D Tumors with Functional Vascularization (TUMOVASC) | Non-small cell bronchopulmonary cancer (NSCLC) | Adults (>18 years) | 100 | NCT04826913 | Strasbourg, France | Observational | Unknown status | 01 April 2021 | 01 April 2024 | Nil |
Organoid-Guided Chemotherapy for Advanced Pancreatic Cancer | Pancreatic cancer | Adults (>18 years) | 100 | NCT04931381 | Shanghai, China | Interventional | Recruiting | 01 June 2021 | 31 May 2025 | Nil |
Organoid-Guided Adjuvant Chemotherapy for Pancreatic Cancer | Pancreatic cancer | Adults (>18 years) | 200 | NCT04931394 | Shanghai, China | Interventional | Recruiting | 01 June /2021 | 31 May 2025 | Nil |
Patient-Tailored Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for Colorectal Peritoneal Metastases (OrganoHIPEC) | Peritoneal metastases from colorectal cancer | Adults | 24 | NCT06057298 | Milan, Italy | Interventional | Recruiting | 15 June 2021 | 14 June 2025 | |
Quadratic Phenotypic Optimization Platform (QPOP) utilization to Enhance Selection of Patient Therapy Through Patient Derived Organoids in Breast Cancer | Breast cancer | Adults | 26 | NCT05177432 | Singapore | Interventional | Recruiting | 06 December 2021 | 31 December 2025 | Nil |
Systemic Neoadjuvant and Adjuvant Control by Precision Medicine in Rectal Cancer (SYNCOPE) | Rectal cancer | Adults (>18 years) | 93 | NCT04842006 | Helsinki, Finland | Interventional | Recruiting | 20 December 2021 | 31 December 2031 | Nil |
Drug Response Profiling (DRP) Registry Zurich for Hematological Malignancies (DRP_ZH) | Primary, relapsed or refractory hematological malignancy (leukemia, myeloma, or lymphoma) | Children and adults (≤40 years) | 1,000 | NCT06550102 | Zurich, Switzerland | Observational | Recruiting | 04 January 2022 | 31 December 2031 | Nil |
Prospective Multicenter Study Evaluating Feasibility and Efficacy of Tumor Organoid-based Precision Medicine in Patients with Advanced Refractory Cancers (ORGANOTREAT) | Advanced solid tumors | Adults (>18 years) | 61 | NCT05267912 | Paris, France | Interventional | Active, not recruiting | 19 January 2022 | 18 January 2028 | |
Tailoring treatment in colorectal cancer | Colorectal neoplasms | Adults | 40 | NCT05401318 | Viken, Norway | Observational | Recruiting | 28 March 2022 | 01 January 2027 | Nil |
The Clinical Efficacy of Drug Sensitive Neoadjuvant Chemotherapy Based on Organoid versus Traditional Neoadjuvant Chemotherapy in Advanced Gastric Cancer | Gastric cancer | Adults ( > 18 years) | 54 | NCT05351398 | Shanghai, China | Observational | Unknown status | 01 April 2022 | 01 December 2023 | Nil |
The Culture of Ovarian Cancer Organoids and Drug Screening | Ovarian cancer | Adults ( > 18 years) | 30 | NCT04768270 | Chongqing, China | Observational | Recruiting | 12 April 2022 | 31 December 2024 | |
Optimizing and Personalizing Azacitidine Combination Therapy for Treating Solid Tumors QPOP and CURATE.AI | Breast or Gastric cancer | Adults | 10 | NCT05381038 | Singapore | Interventional | Not yet recruiting | 01 June 2022 | 04 April 2027 | Nil |
Patient-Derived Organoid (PDO) Guided Versus Conventional Therapy for Advanced Inoperable Abdominal Tumors | Abdominal tumors | Adults ( > 18 years) | 0 | NCT05378048 | Hong Kong | Interventional | Withdrawn | 04 July 2022 | 03 July 2025 | Nil |
Study to Investigate Outcome of Individualized Treatment in Patients with Metastatic Colorectal Cancer (EVIDENT) | Metastatic colorectal cancer | Adults | 40 | NCT05725200 | Oslo, Norway | Interventional | Recruiting | 27 September 2022 | 31 December 2040 | Nil |
The Clinical Efficacy of Drug Sensitive Neoadjuvant Chemotherapy Based on Organoid versus Traditional Neoadjuvant Chemotherapy in Advanced Rectal Cancer | Rectal cancer | Adults ( > 18 years) | 192 | NCT05352165 | Shanghai, China | Interventional | Not yet recruiting | 01 January 2023 | 31 December 2025 | Nil |
FPO to Predict, Prevent, and Treat Early Metastatic Recurrence of TNBC | Recurrent breast cancer | Adults | 80 | NCT05464082 | UT, USA | Interventional | Recruiting | 06 January 2023 | 30 September 2027 | |
Guiding Instillation in Non-Muscle-Invasive Bladder Cancer Based on Drug Screens in PDOs | Bladder cancer/nonmuscle invasive | Adults | 34 | NCT05024734 | Biel, Switzerland | Interventional | Recruiting | 21 February 2023 | 31 October 2027 | |
Ex Vivo Drug Sensitivity Testing and Multi-omics Profiling | Recurrent childhood cancer (all types) | Children | 65 | NCT05857969 | FL, USA | Observational | Recruiting | 22 February 2023 | 31 December 2028 | |
Individualized Treatments in Adults with Relapsed/refractory Cancers | Refractory/relapsed cancer (all types) | Adults | 36 | NCT06024603 | FL, USA | Interventional | Recruiting | 20 November 2023 | 01 November 2025 | Nil |
Pharmacoscopy-Guided Clinical Standard-of-Care in R/r AML (RAPID-01) | Relapsed/refractory AML | Adults | 88 | NCT06138990 | Zurich, Switzerland | Interventional | Recruiting | 02 September 2024 | 30 June 2026 | Nil |
